Сравнение
Cagrilintide vs. Retatrutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
1415456-99-3
2381089-83-2
Молекулярная масса
4253.7 g/mol
4731.6 g/mol
Период полувыведения
168 h
144 h
Последовательность
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSМеханизм действия
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
5
из них на людях
3
4
Зафиксированные эффекты
3
4
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Cagrilintide and Retatrutide?
- Cagrilintide is classified as "Метаболизм", while Retatrutide is classified as "Метаболизм". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Retatrutide?
- The highest available evidence level is "РКИ на людях" for Cagrilintide and "РКИ на людях" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Retatrutide in Germany and the United States?
- Германия: Cagrilintide — Не одобрено, Retatrutide — Не одобрено. США: Cagrilintide — Не одобрено, Retatrutide — Не одобрено. These are factual summaries with source and review date on the individual pages.